Celecoxib | Solubility of Things

Identification

Molecular formula

C₁₇H₁₄F₃N₃O₂S

CAS number

169590-42-5

IUPAC name

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide

State

At room temperature, Celecoxib is in a solid state. It is stable under normal conditions and retains its structural integrity when stored properly.

Melting point (Celsius)

157.00

Melting point (Kelvin)

430.15

Boiling point (Celsius)

235.00

Boiling point (Kelvin)

508.15

General information

Molecular weight

381.37g/mol

Molar mass

381.3720g/mol

Density

1.4850g/cm³

Appearence

Celecoxib appears as a white to off-white crystalline powder. It is practically insoluble in water, with solubility characteristics in various solvents reflecting its chemical stability and pharmacokinetic profile.

Comment on solubility

Solubility of N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide

The solubility of the compound N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide (C₁₇H₁₄F₃N₃O₂S) is influenced by various factors, particularly due to its complex structure that involves multiple functional groups. Here are some key points regarding its solubility:

Polar Functional Groups: The presence of the hydroxyl (-OH) and sulfonyl (-SO₂-) groups generally enhances water solubility, as these groups can form hydrogen bonds with water molecules.
Hydrophobic Aromatic Rings: The incorporation of multiple trifluoromethyl and fluorophenyl substituents contributes to hydrophobicity, which can decrease overall solubility in polar solvents.
Solvent Polarity: This compound may have better solubility in organic solvents (like DMSO or methanol) than in water due to the influence of its fluorinated carbon atoms.
Temperature Dependency: As with many organic compounds, the solubility can increase with temperature, so it may be beneficial to conduct solubility tests at elevated temperatures for a better evaluation.
Potential Formulations: The compound's solubility might be manipulated in pharmaceutical contexts by creating salts or complexes with other solubilizing agents.

In conclusion, while the compound possesses *both hydrophilic* and *hydrophobic* characteristics, understanding its complete solubility profile requires consideration of various factors including the solvent used, temperature, and specific interactions with surrounding molecules. This balance highlights the complexity of predicting solubility behavior for structurally intricate compounds.

Interesting facts

Interesting Facts about N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide

This compound belongs to a fascinating group of organic chemicals characterized by their complex functional groups and potential applications in various fields. Here are some intriguing facts:

Pharmaceutical Applications: The presence of sulfonyl and amide functional groups suggests that this compound could be pivotal in medicinal chemistry, potentially functioning as a *pharmacophore* in drug design.
Fluorine's Role: The trifluoromethyl and fluorophenyl groups enhance the compound's *lipophilicity* and metabolic stability, making it a subject of interest for the development of fluorinated pharmaceuticals.
Significant Biological Activity: Compounds with structural similarities often display notable *biological activities,* ranging from anti-inflammatory to anticancer properties.
Structural Complexity: The intricate arrangement of cyano and hydroxy groups in the molecular structure indicates a potential for engaging in *hydrogen bonding,* which can significantly influence solubility and reactivity.
Research Potential: Scientists are intrigued by the synergy between structural features in this compound, motivating studies to explore its reaction pathways and interaction mechanisms with biomolecules.

Quote from a renowned chemist: "The beauty of chemistry lies in the complexity of its compounds, where each atom tells a different story of reactivity and interaction."

This compound exemplifies the fascinating relationship between structure and function in organic chemistry, opening avenues for extensive research and innovation.

Synonyms

bicalutamide

90357-06-5

Casodex

Cosudex

Calutide

ICI 176334

Bicalutamide (CDX)

ICI-176334

N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide

bicalutamida

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide

ICI 176,334

A0Z3NAU9DP

NSC-759816

DTXSID2022678

C18H14F4N2O4S

MFCD00869971

CHEMBL409

ICI176,334-1

DTXCID00209197

NSC722665

N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

Kalumid

BICALUTAMIDE (MART.)

BICALUTAMIDE [MART.]

Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-

BICALUTAMIDE (USP-RS)

BICALUTAMIDE [USP-RS]

Raffolutil

BICALUTAMIDE (EP MONOGRAPH)

BICALUTAMIDE (USP IMPURITY)

BICALUTAMIDE [EP MONOGRAPH]

BICALUTAMIDE [USP IMPURITY]

BICALUTAMIDE (USP MONOGRAPH)

BICALUTAMIDE [USP MONOGRAPH]

PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-

SMR000466329

Casodex (TN)

CAS-90357-06-5

SR-01000759410

UNII-A0Z3NAU9DP

CHEBI:3090

bicalutamidum

BRN 5364666

Bicadex

Bicalox

Bicamide

Bicatlon

Bicusan

Binabic

Calumid

Calutol

DTXSID501016794

Ormandyl

Bical

Bypro

Propanamide,

CCRIS 8728

HSDB 7655

NCGC00167487-01

(RS)-bicalutamide

racemic bicalutamide

Bicalutamide [USAN:USP:INN:BAN]

(+-)-bicalutamide

(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide

KS-1161

Bicalutamide (Casodex)

CPD000466329

Bicalutamide (Standard)

BICALUTAMIDE [MI]

BICALUTAMIDE [INN]

BICALUTAMIDE [JAN]

BICALUTAMIDE [HSDB]

BICALUTAMIDE [USAN]

SCHEMBL3611

4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

BICALUTAMIDE [VANDF]

-3-(4-fluorophenylsulfonyl)

MLS000759437

MLS001424047

Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-

BICALUTAMIDE [WHO-DD]

-2-hydroxy-2-methylpropanamide

GTPL2863

BDBM18525

Bicalutamide (JP18/USP/INN)

Bicalutamide Crystalline Form II

CHEBI:91617

EX-A962

L02BB03

CHEBI:144093

BCPP000337

BICALUTAMIDE [ORANGE BOOK]

HMS2051B13

HMS2089N12

HMS2232H03

HMS3263M13

HMS3372K05

HMS3393B13

HMS3654K18

HMS3714P13

Pharmakon1600-01504827

BCP02110

SYB76979

Tox21_112488

Tox21_303560

Tox21_501026

HY-14249R

NSC759816

s1190

AKOS015895073

AC-4232

BCP9000408

CCG-100951

CCG-220876

CCG-222330

CS-1296

DB01128

IC58278

LP01026

NC00201

NSC 759816

NSC-722665

SB17301

SDCCGSBI-0633779.P001

4-cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline

N-(4-cyano-3-(trifluoromethyl)phenyl)

NCGC00167977-01

NCGC00167977-02

NCGC00167977-03

NCGC00167977-09

NCGC00167977-20

NCGC00257459-01

NCGC00261711-01

HY-14249

DB-041165

B3206

NS00000400

SW197581-4

Bicalutamide (CDX), >=98% (HPLC), powder

C08160

D00961

AB00639963-06

AB00639963-08

AB00639963-09

AB00639963_10

EN300-1715981

Q1988832

SR-01000759410-4

SR-01000759410-5

BRD-A29485665-001-03-7

BRD-A29485665-001-11-0

BRD-A29485665-001-12-8

Z2108698963

Bicalutamide, British Pharmacopoeia (BP) Reference Standard

Bicalutamide, European Pharmacopoeia (EP) Reference Standard

Bicalutamide, United States Pharmacopeia (USP) Reference Standard

4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide

4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide

4'-Cyano-alpha,alpha,alpha-trifuloro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide

Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard

Bicalutamide, Pharmaceutical Secondary Standard; Certified Reference Material

(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p- fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide

(+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE

(+/-)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide

(RS)-4'-cyano-alpha',alpha',alpha',-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide

N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide

N-(4-Cyano-3-(trifluoromethyl)phenyl)3-3((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-propanamide

N-[(4-CYANO-3-TRIFLUOROMETHYL)PHENYL]-3-[(4-FLUOROPHENYL)SULFONYL]-2-HYDROXY-2-METHYLPROPANAMIDE

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide

N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfinyl]-2-hydroxy-2-methylpropanamide;ICI-176334;Casodex

N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide

N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide

rac-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide